The News
The FDA Just Reset the Conversation on HRT
In November 2025, the FDA began removing most of the black box warning long printed on hormone replacement therapy (HRT) products used for menopause, and on February 12, 2026 it approved the first six revised labels. The boxed warning is the agency's most serious label alert, and for more than two decades it shaped how women and clinicians viewed hormone therapy.
For many women, that warning was the reason they were never offered HRT, or quietly stopped it. The updated position reflects a growing scientific consensus that the original warnings overstated risk for many women, particularly those who begin therapy near the onset of menopause.
At Protocol Health, our family-owned, physician-led team in Scarsdale has followed this evidence closely. Below, we break down what changed, why it matters, and how individualized, lab-informed care fits into the new landscape, in our Scarsdale clinic and by telehealth in NY, NJ, CT, FL, and CA.
Explore Hormone Therapy for WomenQuick Answer
What did the FDA change on HRT labels?
The FDA moved to remove the HRT label's boxed ("black box") warning references to cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy products, and kept the endometrial cancer warning on systemic estrogen-alone products. The agency's position is that the broad warning no longer reflects the balance of evidence for women who use HRT to manage menopausal symptoms.
This does not mean hormone therapy is risk-free or right for everyone. It means the labeling is being brought closer in line with current research, so decisions can be made on individual risk rather than a one-size-fits-all alarm.
The practical takeaway: HRT deserves a fresh, informed conversation with a qualified provider, not automatic avoidance based on a warning written for a different era.
What Stays
What the HRT black box warning said, and what stays on the label
The HRT black box warning said hormone therapy raised concerns about cardiovascular disease, breast cancer and probable dementia; only the endometrial cancer warning stays on the label, for systemic estrogen-alone products. On November 10, 2025, the FDA announced that it is initiating removal of the broad black box warnings from menopausal hormone replacement therapy products. The agency is working with manufacturers to remove boxed-warning references to cardiovascular disease, breast cancer and probable dementia.
The first revised labels have since been approved. On February 12, 2026, the FDA approved labeling changes for six menopausal hormone therapy products, a first batch drawn from all four categories of menopausal HRT. The agency said 29 drug companies had submitted proposed changes at its request.
One boxed warning stays. The FDA is not removing the endometrial cancer warning for systemic estrogen-alone products. Estrogen taken without a progestogen can thicken the lining of the uterus, which is why women who still have a uterus are generally prescribed progesterone alongside estrogen.
The FDA also stated that the labeled recommendation for systemic HRT will be to start within 10 years of menopause onset or before age 60. Removing a warning is a labeling change, not a declaration that HRT is risk-free: the remaining risks, including blood clots and stroke for some women, are still weighed individually by the prescribing physician.
The History
Why were the warnings there in the first place?
The warnings were there in the first place because of the Women's Health Initiative (WHI), whose 2002 estrogen-plus-progestin trial was stopped early, and the FDA's own account is that HRT use plummeted in the early 2000s after the boxed warnings followed.
The 2002 Women's Health Initiative estrogen-plus-progestin trial enrolled 16,608 healthy postmenopausal women aged 50 to 79 and gave them conjugated equine estrogens plus medroxyprogesterone acetate or placebo. After about 5.2 years, the hormone group had more heart disease, stroke, blood clots in the lungs and invasive breast cancer, and fewer hip fractures and colorectal cancers. In absolute terms the excess was small: per 10,000 women a year, about 7 more coronary events, 8 more strokes, 8 more pulmonary emboli and 8 more breast cancers. According to the FDA, the average participant was 63 years old, more than a decade past the typical age of menopause, and took a hormone formulation no longer in common use.
In the years since, researchers have revisited that data under the "timing hypothesis." Later analyses suggested that for many women who begin HRT closer to menopause, typically under 60 or within ten years of their final period, the benefit-risk picture can look meaningfully different from what the original headlines implied. The label, however, lagged behind the evolving science for years.
What Changed
How the evidence evolved
The evidence evolved to show that hormone therapy risks differ by timing, type, dose and route, so a blanket boxed warning no longer fit. Menopause specialists and major medical societies have argued for some time that a blanket boxed warning discouraged appropriate care and contributed to years of undertreated menopausal symptoms, including hot flashes, night sweats, sleep disruption, mood changes, and genitourinary symptoms.
Route of delivery and formulation matter. The North American Menopause Society's 2022 position statement says the risks of hormone therapy differ by type, dose, duration, route of administration, timing of initiation, and whether a progestogen is used. Transdermal estrogen (patches, gels) is therefore weighed differently from the older oral regimen the WHI studied, though every option carries its own considerations that a provider must weigh.
The FDA's move acknowledges this nuance. Rather than a single warning applied broadly, the emphasis shifts toward individualized assessment, which is how modern hormone care should work.
Why It Matters
What this means for women considering HRT
For women considering HRT, especially those who hesitated because of the old warning, this means an invitation to have an evidence-based conversation rather than a reason to start therapy on impulse. HRT may help many women manage disruptive menopausal symptoms and support quality of life, but suitability is always individual and determined with a provider.
It also matters for how care is delivered. The change reinforces that hormone therapy should be guided by your personal and family history, current labs, symptoms, and goals, not by a headline or a decades-old assumption.
If you stopped HRT years ago, or were never offered it, this can be a reasonable moment to revisit the question with a physician who treats hormone health as a core specialty rather than an afterthought.
Candidacy
Who is typically a candidate for hormone therapy?
Hormone replacement therapy is most often considered for women experiencing menopausal or perimenopausal symptoms such as hot flashes, night sweats, sleep disturbance, mood shifts, brain fog, low libido, or vaginal and urinary symptoms. Women within roughly ten years of their final period or under 60 are frequently part of the conversation, though age alone is never the sole factor.
That timing matches the 2022 hormone therapy position statement of The North American Menopause Society (now The Menopause Society): for women under 60, or within 10 years of menopause onset and without contraindications, the benefit-risk balance is favorable for treating bothersome hot flashes and night sweats and for preventing bone loss. For women who start more than 10 years after menopause or after 60, it appears less favorable.
Candidacy depends on your full clinical picture: personal and family history (including breast cancer, blood clots, and cardiovascular disease), current symptoms, and lab results. Some women are better served by non-hormonal approaches, and a good provider will say so.
The only way to know whether HRT fits you is an individualized evaluation. Protocol Health's Female Hormone and Longevity Assessment, held at our Scarsdale clinic, is designed for exactly this kind of thorough, lab-informed review.
Safety
Is hormone replacement therapy safe?
Hormone replacement therapy is not entirely without risk, since no medical therapy is. Potential considerations can include effects on blood clots, breast tissue, and cardiovascular health, and these vary by a woman's age, health history, formulation, and how therapy is delivered.
The updated FDA stance does not erase these considerations; it corrects an overstatement so that real risks can be weighed honestly against potential benefits for each individual. That is a more accurate foundation for a decision, not a reason to skip caution.
This is why physician supervision, appropriate lab work, and ongoing monitoring matter. Therapy is reviewed over time and adjusted as needed, and any new symptoms are evaluated promptly. This article is educational and not a substitute for personalized medical advice.
What to Expect
What the process looks like at Protocol Health
The process at Protocol Health looks like this: care begins with a conversation and a comprehensive assessment of your symptoms, history, and goals. From there, we typically order lab work, which may include hormone panels and other markers, to build an accurate picture before recommending anything.
If hormone therapy is appropriate, your physician discusses options, which may include estrogen creams or gels, patches, vaginal estrogen, oral progesterone, or low-dose testosterone for women, and explains the reasoning behind each choice. Dosing is individualized, and you are monitored and adjusted over time.
In-person visits take place at our Scarsdale clinic. Telehealth care is available in NY, NJ, CT, FL, and CA, with the same physician-led attention to detail.
Our Approach
Physician-led hormone care, built around you
Protocol Health is a family-owned, physician-led clinic where hormone optimization is a core focus, not a side offering. Our clinical team treats menopause and hormone health as an individualized, data-driven discipline, combining careful labs, current evidence, and ongoing follow-up.
The FDA's removal of the black box warning on HRT for heart disease, breast cancer and dementia, with the endometrial cancer warning kept, is a welcome step toward the kind of nuanced, personalized care we already practice. It gives women room to ask better questions, and it gives clinicians a more honest starting point.
If you have been curious about HRT, or set it aside because of old fears, we would be glad to help you understand your options based on your body and your goals, not a warning label from another era.
FAQ
Frequently Asked Questions
Did the FDA say hormone replacement therapy is completely safe now?
No. The FDA removed most of the boxed warning because it overstated risk for many women, but hormone therapy still carries considerations that vary by individual. The change supports informed, individualized decisions rather than declaring HRT risk-free. A qualified provider should always assess your personal history and labs first.
Which black box warning was removed from HRT, and which one stays?
The FDA is removing boxed-warning references to cardiovascular disease, breast cancer and probable dementia from menopausal HRT labels. It is keeping the boxed warning for endometrial cancer on systemic estrogen-alone products, which is why women with a uterus are usually prescribed a progestogen with estrogen.
Why were women told to avoid HRT for so long?
The 2002 Women's Health Initiative trial found small absolute increases in breast cancer, heart disease, stroke and blood clots with one combined regimen, and HRT use fell sharply afterward. Later analyses noted the study population averaged 63, older and further from menopause than typical HRT users, which changed the interpretation. The labeling took years to catch up with that evolving evidence.
Is it too late to start HRT if I went through menopause years ago?
Not necessarily, but timing is one important factor among many. Research suggests the benefit-risk picture is often most favorable for women who begin closer to menopause, generally under 60 or within about ten years of their final period. The right answer depends on your full clinical picture, which is best determined through an individualized evaluation with a physician.
What types of hormone therapy are available for women?
Options can include estrogen creams or gels, estrogen patches, vaginal estrogen, oral progesterone, and low-dose testosterone for women, among others. The best choice depends on your symptoms, history, and goals, and is determined with your physician. Dosing is individualized and monitored over time.
Do I need lab work before starting hormone therapy?
In most cases, yes. Lab work helps build an accurate picture of your hormone levels and overall health before any therapy is recommended, and supports safe monitoring afterward. At Protocol Health, hormone care is lab-informed and physician-supervised from the start.
Can I do this through telehealth if I am not in Scarsdale?
Often, yes. Protocol Health offers telehealth to patients in NY, NJ, CT, FL, and CA, and many aspects of hormone care can be handled that way. In-person visits are at our Scarsdale clinic. Your physician will advise on what makes sense for your situation.
Explore
Related at Protocol Health
Explore Hormone Therapy for WomenThis article is educational and is not medical advice. It does not diagnose, prevent, treat or cure any condition. Talk with a licensed clinician about your own situation.